THE EFFECT OF THE GLUCAGON SUPPRESSORS PRAMLINTIDE AND EXENATIDE ON POSTPRANDIAL

胰高血糖素抑制剂普兰林肽和艾塞那肽对餐后的影响

• 批准号: 8356705
• 负责人: LUISA M RODRIGUEZ
• 金额: $ 1.42万
• 依托单位: BAYLOR COLLEGE OF MEDICINE
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-12-01 至 2011-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8356705
• 关键词: Adult; Agonist; Child; Childhood; Clinical Research; Diabetes Mellitus; Dose; Funding; Glucagon; Glucose; Grant; Hyperglycemia; Incidence; Insulin; Laboratories; National Center for Research Resources; Non-Insulin-Dependent Diabetes Mellitus; Patients; Population; Pramlintide; Principal Investigator; Research; Research Infrastructure; Resources; Source; Testing; United States National Institutes of Health; analog; cost; exenatide; glucagon-like peptide 1; glycemic control; hyperglucagonemia; improved; islet amyloid polypeptide; macrovascular disease; prevent; receptor

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. Primary support for the subproject and the subproject's principal investigator may have been provided by other sources, including other NIH sources. The Total Cost listed for the subproject likely represents the estimated amount of Center infrastructure utilized by the subproject, not direct funding provided by the NCRR grant to the subproject or subproject staff. ABSTRACT The use of glucagon suppressors pramlintide and exenatide is well established in adult patients with T2DM, but there is a lack of information regarding an effective glucose lowering effect in pediatric T2DM. Previous studies from our laboratory showed that there is unabated early postprandial hyperglucagonemia in children with T2DM contributing to the marked postprandial hyperglycemia. There is insulin, amylin and GLP-1 deficiency in children with T2DM requiring insulin therapy. Both amylin and GLP-1 are potent endogenous glucagon suppressors. The glucose and glucagon lowering effect of the amylin analog pramlintide and the GLP-1 receptor agonist exenatide will be tested in insulin requiring children with T2DM. The lowest adult recommended doses would be used. With an increasing incidence of T2DM in the pediatric population, it is incumbent upon us to research new therapies in an effort to improve glycemic control and prevent the long-term micro and macrovascular complications associated with diabetes.

该子项目是利用资源的众多研究子项目之一 由 NIH/NCRR 资助的中心拨款提供。子项目的主要支持 并且子项目的主要研究者可能是由其他来源提供的， 包括其他 NIH 来源。 子项目可能列出的总成本 代表子项目使用的中心基础设施的估计数量， NCRR 赠款不直接向子项目或子项目工作人员提供资金。 抽象的 胰高血糖素抑制剂普兰林肽和艾塞那肽在成年 T2DM 患者中的使用已得到广泛认可，但缺乏有关儿童 T2DM 有效降血糖作用的信息。我们实验室之前的研究表明，T2DM 儿童的早期餐后高血糖素血症有增无减，导致显着的餐后高血糖。需要胰岛素治疗的 T2DM 儿童存在胰岛素、胰岛淀粉样多肽和 GLP-1 缺乏。胰淀素和 GLP-1 都是有效的内源性胰高血糖素抑制剂。胰岛淀粉样多肽类似物普兰林肽和 GLP-1 受体激动剂艾塞那肽的降血糖和胰高血糖素作用将在需要胰岛素的 T2DM 儿童中进行测试。将使用成人推荐的最低剂量。随着儿科人群中 T2DM 发病率的不断增加，我们有责任研究新疗法，以改善血糖控制并预防与糖尿病相关的长期微血管和大血管并发症。